Search Results - "metastasis"
Suggested Topics within your search.
Suggested Topics within your search.
- Neovascularization, Physiologic
- Angiogenesis Inducing Agents 6
- Antagonists 6
- Monoclonal antibodies 6
- Receptors, Vascular Endothelial Growth Factor 6
- Signal Transduction 6
- Vascular Endothelial Growth Factor Receptor-3 6
- Vascular endothelial growth factors 6
- antagonists & inhibitors 6
- metabolism 6
- Angiogenesis Inhibitors 3
- Antibodies, Monoclonal 3
- Colorectal Neoplasms 3
- Neoplasms 3
- Neovascularization inhibitors 3
- Vascular Endothelial Growth Factors 3
- complications 3
- drug therapy 3
- pharmacology 3
- therapy 3
-
1
VEGF inhibitors for anti-angiogenic therapy
Published 2007Table of Contents: “…Contents: Antagonist monoclonal antibodies to VEGFR-3 -- Mode of action of antagonist monoclonal antibodies -- Functional properties of antagonist antibodies to VEGFR-3 -- In vivo effects of anti-VEGFR-3 treatment on physiological lymphangiogenesis -- Inhibition of pathological vessel growth in the cornea -- Anti-angiogenic effect of antibodies to VEGFR-3 in tumors -- Inhibition of lymphatic metastasis with antagonist antibodies to VEGFR-3 -- Role of VEGFR-3 in normal and pathological immune response.…”
Get full text
Series
Electronic Video -
2
VEGF inhibitors for anti-angiogenic therapy
Published 2007Table of Contents: “…Contents: Antagonist monoclonal antibodies to VEGFR-3 -- Mode of action of antagonist monoclonal antibodies -- Functional properties of antagonist antibodies to VEGFR-3 -- In vivo effects of anti-VEGFR-3 treatment on physiological lymphangiogenesis -- Inhibition of pathological vessel growth in the cornea -- Anti-angiogenic effect of antibodies to VEGFR-3 in tumors -- Inhibition of lymphatic metastasis with antagonist antibodies to VEGFR-3 -- Role of VEGFR-3 in normal and pathological immune response.…”
Get full text
Series
Electronic Video -
3
VEGF inhibitors for anti-angiogenic therapy
Published 2007Table of Contents: “…Contents: Antagonist monoclonal antibodies to VEGFR-3 -- Mode of action of antagonist monoclonal antibodies -- Functional properties of antagonist antibodies to VEGFR-3 -- In vivo effects of anti-VEGFR-3 treatment on physiological lymphangiogenesis -- Inhibition of pathological vessel growth in the cornea -- Anti-angiogenic effect of antibodies to VEGFR-3 in tumors -- Inhibition of lymphatic metastasis with antagonist antibodies to VEGFR-3 -- Role of VEGFR-3 in normal and pathological immune response.…”
Get full text
Series
Electronic Video -
4
VEGF inhibitors for anti-angiogenic therapy
Published 2007Table of Contents: “…Contents: Antagonist monoclonal antibodies to VEGFR-3 -- Mode of action of antagonist monoclonal antibodies -- Functional properties of antagonist antibodies to VEGFR-3 -- In vivo effects of anti-VEGFR-3 treatment on physiological lymphangiogenesis -- Inhibition of pathological vessel growth in the cornea -- Anti-angiogenic effect of antibodies to VEGFR-3 in tumors -- Inhibition of lymphatic metastasis with antagonist antibodies to VEGFR-3 -- Role of VEGFR-3 in normal and pathological immune response.…”
Get full text
Series
Electronic Video -
5
VEGF inhibitors for anti-angiogenic therapy
Published 2007Table of Contents: “…Contents: Antagonist monoclonal antibodies to VEGFR-3 -- Mode of action of antagonist monoclonal antibodies -- Functional properties of antagonist antibodies to VEGFR-3 -- In vivo effects of anti-VEGFR-3 treatment on physiological lymphangiogenesis -- Inhibition of pathological vessel growth in the cornea -- Anti-angiogenic effect of antibodies to VEGFR-3 in tumors -- Inhibition of lymphatic metastasis with antagonist antibodies to VEGFR-3 -- Role of VEGFR-3 in normal and pathological immune response.…”
Get full text
Series
Electronic Video -
6
VEGF inhibitors for anti-angiogenic therapy
Published 2007Table of Contents: “…Contents: Antagonist monoclonal antibodies to VEGFR-3 -- Mode of action of antagonist monoclonal antibodies -- Functional properties of antagonist antibodies to VEGFR-3 -- In vivo effects of anti-VEGFR-3 treatment on physiological lymphangiogenesis -- Inhibition of pathological vessel growth in the cornea -- Anti-angiogenic effect of antibodies to VEGFR-3 in tumors -- Inhibition of lymphatic metastasis with antagonist antibodies to VEGFR-3 -- Role of VEGFR-3 in normal and pathological immune response.…”
Get full text
Series
Electronic Video -
7
Changing paradigms in anticancer drug development inhibiting angiogenesis in colorectal cancer /
Published 2009Table of Contents: “…Contents: Targeted therapy for cancer -- Angiogenesis is involved throughout tumour formation, growth and metastasis -- VEGF: molecular characteristics -- VEGF and other signals promote the angiogenic switch in tumours -- Tumour vasculature is abnormal -- VEGF produces immature tortuous vessels dependent on VEGF for survival -- Other features make VEGF an attractive target for anticancer therapy -- RhuMAb VEGF (bevacizumab/Avastin®) -- Significant reduction in microvasculature -- Anti-VEGF antibody improves drug delivery -- Avastin: an anti-VEGF agent for cancer therapy -- Use of Avastin with oxaliplatin-based therapy -- Addition of Avastin to oxaliplatin-based chemotherapy improved best confirmed response -- Study schema and organization.…”
Get full text
Series
Electronic Video -
8
Changing paradigms in anticancer drug development inhibiting angiogenesis in colorectal cancer /
Published 2009Table of Contents: “…Contents: Targeted therapy for cancer -- Angiogenesis is involved throughout tumour formation, growth and metastasis -- VEGF: molecular characteristics -- VEGF and other signals promote the angiogenic switch in tumours -- Tumour vasculature is abnormal -- VEGF produces immature tortuous vessels dependent on VEGF for survival -- Other features make VEGF an attractive target for anticancer therapy -- RhuMAb VEGF (bevacizumab/Avastin®) -- Significant reduction in microvasculature -- Anti-VEGF antibody improves drug delivery -- Avastin: an anti-VEGF agent for cancer therapy -- Use of Avastin with oxaliplatin-based therapy -- Addition of Avastin to oxaliplatin-based chemotherapy improved best confirmed response -- Study schema and organization.…”
Get full text
Series
Electronic Video -
9
Changing paradigms in anticancer drug development inhibiting angiogenesis in colorectal cancer /
Published 2009Table of Contents: “…Contents: Targeted therapy for cancer -- Angiogenesis is involved throughout tumour formation, growth and metastasis -- VEGF: molecular characteristics -- VEGF and other signals promote the angiogenic switch in tumours -- Tumour vasculature is abnormal -- VEGF produces immature tortuous vessels dependent on VEGF for survival -- Other features make VEGF an attractive target for anticancer therapy -- RhuMAb VEGF (bevacizumab/Avastin®) -- Significant reduction in microvasculature -- Anti-VEGF antibody improves drug delivery -- Avastin: an anti-VEGF agent for cancer therapy -- Use of Avastin with oxaliplatin-based therapy -- Addition of Avastin to oxaliplatin-based chemotherapy improved best confirmed response -- Study schema and organization.…”
Get full text
Series
Electronic Video
